{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T18:59:00Z","timestamp":1789239540123,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T00:00:00Z","timestamp":1693440000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.jdiacomp.2023.108588","type":"journal-article","created":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T03:22:23Z","timestamp":1692242543000},"page":"108588","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Changes in cardiac and vascular haemodynamics as potential mediators of improvements in cardiovascular and kidney outcomes with empagliflozin in type 2 diabetes"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1718-2918","authenticated-orcid":false,"given":"Bernhard K.","family":"Kr\u00e4mer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3319-3710","authenticated-orcid":false,"given":"Sibylle J.","family":"Hauske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0195-5063","authenticated-orcid":false,"given":"Robert","family":"Chilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3154-5332","authenticated-orcid":false,"given":"Johannes F.E.","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5932-6641","authenticated-orcid":false,"given":"Lars","family":"Gullestad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1312-5983","authenticated-orcid":false,"given":"David","family":"Fitchett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8611-6236","authenticated-orcid":false,"given":"Michaela","family":"Mattheus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7783-8560","authenticated-orcid":false,"given":"Dominik","family":"Steubl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9507-5301","authenticated-orcid":false,"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2023.108588_bb0005","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2023.108588_bb0010","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2023.108588_bb0015","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/eurheartj\/ehv728","article-title":"Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial","volume":"37","author":"Fitchett","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jdiacomp.2023.108588_bb0020","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2023.108588_bb0025","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1093\/ndt\/gfz179","article-title":"Choice of endpoint in kidney outcome trials: considerations from the EMPA-REG OUTCOME(R) trial","volume":"35","author":"Perkovic","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jdiacomp.2023.108588_bb0030","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1002\/ehf2.13615","article-title":"Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial","volume":"8","author":"Fitchett","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jdiacomp.2023.108588_bb0035","doi-asserted-by":"crossref","first-page":"356","DOI":"10.2337\/dc17-1096","article-title":"How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial","volume":"41","author":"Inzucchi","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2023.108588_bb0040","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jash.2014.01.007","article-title":"Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis","volume":"8","author":"Baker","year":"2014","journal-title":"J Am Soc Hypertens"},{"key":"10.1016\/j.jdiacomp.2023.108588_bb0045","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/dom.12244","article-title":"Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials","volume":"16","author":"Monami","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2023.108588_bb0050","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/ajh.2012.3","article-title":"Predictive value for mortality of the double product at rest obtained by home blood pressure measurement: the Ohasama study","volume":"25","author":"Inoue","year":"2012","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.jdiacomp.2023.108588_bb0055","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1161\/HYPERTENSIONAHA.112.197210","article-title":"Large artery stiffening and remodeling are independently associated with all-cause mortality and cardiovascular events in chronic kidney disease","volume":"60","author":"Karras","year":"2012","journal-title":"Hypertension."},{"key":"10.1016\/j.jdiacomp.2023.108588_bb0060","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.amjcard.2013.12.005","article-title":"Meta-analysis of the quantitative relation between pulse pressure and mean arterial pressure and cardiovascular risk in patients with diabetes mellitus","volume":"113","author":"Kodama","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jdiacomp.2023.108588_bb0065","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.semnephrol.2018.02.003","article-title":"Cardiovascular disease and diabetic kidney disease","volume":"38","author":"Maqbool","year":"2018","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.jdiacomp.2023.108588_bb0070","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1093\/eurheartj\/ehq024","article-title":"Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis","volume":"31","author":"Vlachopoulos","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jdiacomp.2023.108588_bb0075","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1111\/jch.14067","article-title":"Association of double product and pulse pressure with cardiovascular and all-cause mortality in the LURIC study","volume":"22","author":"Yazdani","year":"2020","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.jdiacomp.2023.108588_bb0080","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1475-2840-13-28","article-title":"The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus","volume":"13","author":"Cherney","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2023.108588_bb0085","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/dom.12572","article-title":"Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes","volume":"17","author":"Chilton","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2023.108588_bb0090","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jdiacomp.2023.108588_bb0095","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1037\/0022-3514.51.6.1173","article-title":"The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations","volume":"51","author":"Baron","year":"1986","journal-title":"J Pers Soc Psychol"},{"key":"10.1016\/j.jdiacomp.2023.108588_bb0100","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.jacc.2021.07.049","article-title":"Empagliflozin improves cardiovascular and renal outcomes in heart failure irrespective of systolic blood pressure","volume":"78","author":"B\u00f6hm","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jdiacomp.2023.108588_bb0105","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.diabet.2009.04.010","article-title":"Pulse pressure strongly predicts cardiovascular disease risk in patients with type 2 diabetes from the Swedish National Diabetes Register (NDR)","volume":"35","author":"Nilsson","year":"2009","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.jdiacomp.2023.108588_bb0110","doi-asserted-by":"crossref","first-page":"8714745","DOI":"10.1155\/2016\/8714745","article-title":"Interaction between mean arterial pressure and HbA1c in prediction of cardiovascular disease hospitalisation: a population-based case-control study","volume":"2016","author":"Yu","year":"2016","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.jdiacomp.2023.108588_bb0115","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/ajh\/hps119","article-title":"Double product reflects the predictive power of systolic pressure in the general population: evidence from 9,937 participants","volume":"26","author":"Schutte","year":"2013","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.jdiacomp.2023.108588_bb0120","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12933-017-0511-0","article-title":"Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis","volume":"16","author":"Pfeifer","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2023.108588_bb0125","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S0140-6736(21)01921-8","article-title":"Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis","volume":"398","author":"Blood Pressure Lowering Treatment Trialists C","year":"2021","journal-title":"Lancet."},{"key":"10.1016\/j.jdiacomp.2023.108588_bb0130","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2023.108588_bb0135","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2023.108588_bb0140","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2023.108588_bb0150","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.kint.2020.10.031","article-title":"Characterization and implications of the initial estimated glomerular filtration rate \u201cdip\u201d upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial","volume":"99","author":"Kraus","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.jdiacomp.2023.108588_bb0155","doi-asserted-by":"crossref","first-page":"836849","DOI":"10.3389\/fphar.2022.836849","article-title":"Emerging roles of sodium glucose cotransporter 2 (SGLT-2) inhibitors in diabetic cardiovascular diseases: focusing on immunity, inflammation and metabolism","volume":"13","author":"Xie","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jdiacomp.2023.108588_bb0160","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12933-020-01071-y","article-title":"SGLT2i: beyond the glucose-lowering effect","volume":"19","author":"Ni","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2023.108588_bb0165","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jchf.2019.08.004","article-title":"Mediators of the effects of canagliflozin on heart failure in patients with type 2 diabetes","volume":"8","author":"Li","year":"2020","journal-title":"JACC Heart Fail"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872723001861?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872723001861?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:18:14Z","timestamp":1761005894000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872723001861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S1056872723001861"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2023.108588","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Changes in cardiac and vascular haemodynamics as potential mediators of improvements in cardiovascular and kidney outcomes with empagliflozin in type 2 diabetes","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2023.108588","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors.","name":"copyright","label":"Copyright"}],"article-number":"108588"}}